Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Patients With Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 17 of 29

Target Doses for ACEIs and ARBs in Trials Investigating the Addition of an ACEI or an ARB to Standard Medical Therapy for Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

This table summarizes the daily target dose of the angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II-receptor blocker (ARB) used in the randomized placebo-controlled clinical trials that met the inclusion criteria for the comparative effectiveness review (CER). The patients enrolled in these trials had stable ischemic heart disease and preserved left ventricular systolic function and were randomized to receive standard medical therapy alone or standard medical therapy combined with an ACEI or an ARB. Available evidence is insufficient to determine if different doses of ACEIs or ARBs impact outcomes in this patient population.

For further details on the dosing regiments that were used in the trials reviewed in this CER, please refer to the original comparative effectiveness review on which this slide is based (available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=335).